DRMA | Dermata Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.4300 - 1.6350
52 Week Range	1.2900 - 17.85
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	63,029
Average Volume	2,223,495
Shares Outstanding	1,315,981
Market Cap	2,079,250
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-08-13

Valuation
Profitability
Growth
Health
P/E Ratio	-0.08
Forward P/E Ratio	N/A
EPS	-18.73
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	DRMA

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

DRMA's peers: ADTX, APM, CGTX, CUE, ZURA, PHIO, SONN, ATNF, CDIO, WINT, ENSC, PBLA, BXRX, ZVSA, REVB, NAVB, CYTO, IMMX, HEPA, AVRO, EFTR, DRUG, AUGX, INMB, IPA, ITRM, MBIO, NBTX, PSTV, SNGX, TCRX, TENX, TFFP, UBX, VTGN, PRST, SPRY, COYA

*Chart delayed

Analyzing fundamentals for DRMA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see DRMA Fundamentals page.

Watching at DRMA technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on DRMA Technicals page.